UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

Journal of medical economics, 2023-12, Vol.26 (1), p.835-842

2023

Volltextzugriff (PDF)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective

Saudi pharmaceutical journal, 2022-04, Vol.30 (4), p.433-439

2022

Volltextzugriff (PDF)

The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region

Expert opinion on biological therapy, 2023-08, Vol.ahead-of-print (ahead-of-print), p.1-7

2023

Volltextzugriff (PDF)

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

JAMA dermatology (Chicago, Ill.), 2019-01, Vol.155 (1), p.22

2019

Volltextzugriff (PDF)

The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs—Reply

JAMA dermatology (Chicago, Ill.), 2019-07, Vol.155 (7), p.863

2019

Volltextzugriff (PDF)

Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective

The Annals of pharmacotherapy, 2023-09, Vol.57 (9), p.1016-1024

2023

Volltextzugriff (PDF)

The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs

Journal of medical economics, 2024-12, Vol.27 (1), p.880-886

2024

Volltextzugriff (PDF)

Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting

Current medical research and opinion, 2022-04, Vol.38 (4), p.571-577

2022

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: δ3: reference-based pricing

Journal of medical economics, 2020-11, Vol.23 (11), p.1230-1236

2020

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing

Journal of medical economics, 2020-11, Vol.23 (11), p.1215-1222

2020

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing

Journal of medical economics, 2020-11, Vol.23 (11), p.1223-1229

2020

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)

Journal of medical economics, 2020-11, Vol.23 (11), p.1266-1272

2020

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing

Journal of medical economics, 2020-11, Vol.23 (11), p.1246-1255

2020

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: δ4: safety-based pricing

Journal of medical economics, 2020-11, Vol.23 (11), p.1237-1245

2020

Volltextzugriff (PDF)

Pricing methods in outcome-based contracting: δ6: adherence-based pricing

Journal of medical economics, 2020-11, Vol.23 (11), p.1256-1265

2020

Volltextzugriff (PDF)

Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study

Journal of medical economics, 2018-12, Vol.21 (12), p.1246-1253

2018

Volltextzugriff (PDF)

The six Delta platform for outcome-based contracting for pharmaceuticals

Journal of medical economics, 2020-11, Vol.23 (11), p.1209-1214

2020

Volltextzugriff (PDF)

Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8043-8043

2021

Volltextzugriff (PDF)

Economic evaluation of crizotinib, alectinib, ceritinib, and brigatininb in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second-line treatment

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21104-e21104

2021

Volltextzugriff (PDF)

Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21102-e21102

2021

Volltextzugriff (PDF)

Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20515-e20515

2019

Volltextzugriff (PDF)

Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20714-e20714

2019

Volltextzugriff (PDF)

30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16597-e16597

2019

Volltextzugriff (PDF)

Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5583-5583

2020

Volltextzugriff (PDF)

Innovative Methods for Outcome-Based Pricing of Treatments from the US Payer Perspective (The Six Delta Platform)

Alkhatib, Nimer S

2020

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(40)
Dissertationen
(1)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective

The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs—Reply

Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective

The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs

Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting

Pricing methods in outcome-based contracting: δ3: reference-based pricing

Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing

Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing

Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)

Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing

Pricing methods in outcome-based contracting: δ4: safety-based pricing

Pricing methods in outcome-based contracting: δ6: adherence-based pricing

Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study

The six Delta platform for outcome-based contracting for pharmaceuticals

Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis

Economic evaluation of crizotinib, alectinib, ceritinib, and brigatininb in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second-line treatment

Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS)

Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa)

Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Innovative Methods for Outcome-Based Pricing of Treatments from the US Payer Perspective (The Six Delta Platform)

Suchergebnisse filtern